Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
08 nov. 2023 16h01 HE
|
Fate Therapeutics, Inc.
Phase 1 Study Open for Enrollment of FT522 ADR-armed, CD19-targeted CAR NK Cell Program for B-cell Lymphoma; Dose Escalation Designed to Assess 3-dose Treatment Schedule with and without Conditioning...
Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results
25 oct. 2023 08h00 HE
|
Fate Therapeutics, Inc.
SAN DIEGO, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a...
Fate Therapeutics to Present at Upcoming September Investor Conferences
31 août 2023 08h00 HE
|
Fate Therapeutics, Inc.
SAN DIEGO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a...
Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates
08 août 2023 16h01 HE
|
Fate Therapeutics, Inc.
Phase 1 Study Start-up Ongoing for FT522 ADR-armed, CD19-targeted CAR NK Cell Program for B-cell Lymphoma; Dose Escalation Designed to Assess 3-dose Treatment Schedule with and without Conditioning...
Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results
28 juil. 2023 08h00 HE
|
Fate Therapeutics, Inc.
SAN DIEGO, July 28, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a...
Fate Therapeutics to Present at Upcoming June Investor Conferences
31 mai 2023 08h00 HE
|
Fate Therapeutics, Inc.
SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a...
Fate Therapeutics Reports First Quarter 2023 Financial Results and Business Updates
03 mai 2023 16h01 HE
|
Fate Therapeutics, Inc.
Dose Escalation Ongoing in Landmark Phase 1 Study of FT819 CD19-targeted 1XX CAR T-cell Program; Interim Clinical Data Demonstrated Favorable Safety Profile and Complete Responses in Aggressive Large...
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2023 Financial Results
24 avr. 2023 08h00 HE
|
Fate Therapeutics, Inc.
SAN DIEGO, April 24, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a...
Fate Therapeutics to Present at Upcoming March Investor Conferences
03 mars 2023 16h01 HE
|
Fate Therapeutics, Inc.
SAN DIEGO, March 03, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a...
Fate Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
28 févr. 2023 16h01 HE
|
Fate Therapeutics, Inc.
Ended 2022 with Approximately $475 Million in Cash, Cash Equivalents, and Receivables Multi-dose Treatment Cohorts Initiated in FT576 Phase 1 Study for Multiple Myeloma; Interim Clinical Data from...